TABLE 2.
The ferroptosis inhibitors.
| Affected pathways | Inhibitors | Mechanism | References |
|---|---|---|---|
| Iron metabolism | Ferrostatin-1 | Eliminate unstable iron and ROS | Dixon et al. (2012) |
| Curcumin | Suppressed erastin, regulated NRF2/HO-1 pathway | Yang et al. (2021) | |
| lipid peroxidation pathway | Vitamin E | Suppressed LOX | Kagan et al. (2017) |
| Baicalein | Regulated GPX4/ACSL4/ACSL3 axis, suppressed lipid peroxidation | Li et al. (2022b) | |
| Thiazolidinedione (TZD) | Selectively suppressed ACSL4 | Doll et al. (2017) | |
| Lliproxstatin-1 | Suppressed mitochondrial lipid peroxidation and reduced MDA levels and it upregulated GSH, GPX4 and FSP1 | Fan et al. (2021) | |
| Zileuton | Specificly inhibited 5-LOX | Liu et al. (2015) | |
| Amino acid metabolic pathway | BRD4770 | Inhibition of the System Xc--GPX4 pathway | Chen et al. (2022) |
| Other metabolic pathways | Vitamin K | FSP1-dependent nonclassical vitamin K cycle | Mishima et al. (2022) |